The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://m.youtube.com/watch?v=vR1naceENaU
Good video from CryptoRUs explaining market manipulation and BTC exchange outflows etc.
https://m.youtube.com/watch?v=HO8vuG9eKLU
Funky finance video - good watch if you haven't already seen it. GLA.
IMV, the potential lies in licencing the tech. I am hopeful the BOD are pursuing every avenue to maximize the opportunity. Hoping for news soon. GLA holders.
Ed McDermott (FFWD CEO) tweet.
https://twitter.com/edmcdermott12/status/1370095972307632135
https://www.braintumourresearch.org/campaigning/brain-tumour-research-petition#signnow
Sign our petition calling for increased national investment into brain tumour research to £35 million a year.
The biggest cancer killer of children and adults under the age of 40.
Brain tumours still kill more children and adults under the age of 40 than any other cancer, yet despite promises of increased investment in research from the Government and larger cancer charities we are still not seeing parity of funding with other cancers such as breast, prostate and leukaemia.
More children and adults under the age of 40 die of a brain tumour than any other cancer
Five-year survival for breast and prostate is over 70%, leukaemia over 40% yet for brain tumours it is just 12%
Since national cancer spend records began in 2002, £680 million has been invested in breast cancer, yet only £96 million in brain tumours – that’s a difference of £35 million a year over 17 years
-
So sad, had no idea brain tumours were the highest cause of death in <40year olds. IB's software is much needed (understatement?)
*not posting using phone again - unreadable.
*Apologies for posting link to petition - It was the sad facts I wanted to highlight as I was completely unaware of the size of the issue.
https://www.braintumourresearch.org/campaigning/brain-tumour-research-petition#signnowSign our petition calling for increased national investment into brain tumour research to £35 million a yearThe biggest cancer killer of children and adults under the age of 40Brain tumours still kill more children and adults under the age of 40 than any other cancer, yet despite promises of increased investment in research from the Government and larger cancer charities we are still not seeing parity of funding with other cancers such as breast, prostate and leukaemia.More children and adults under the age of 40 die of a brain tumour than any other cancerFive-year survival for breast and prostate is over 70%, leukaemia over 40% yet for brain tumours it is just 12%Since national cancer spend records began in 2002, £680 million has been invested in breast cancer, yet only £96 million in brain tumours – that’s a difference of £35 million a year over 17 years-So sad, had no idea brain tumours were the highest cause of death in <40year olds. IB's software is much needed (understatement?)
For balance, the same can be said of the derampers also. I remember (without mentioning names) the same type of posts when FFWD updated their investment strategy in June 2020 to increase the ability to issue more shares. The negative sentiment was overwhelming at the time.
FWIW, I believe sentiment is at play here again and we are oversold and undervalued :) imv.
The cynic in me questions why post when you are not invested but it's good to hear both sides.
GLA LTH. I have faith in Ed FWIW. Anyone know Peter Salvino's AVG? Thks.
The most recent NAV value is 9.43p from Dec 20 Interim Results.
-
The net assets of the Company at 30 September 2020 were £15,224,000 (31 March 2020: £14,238,000), equal to net assets of 9.43p per Ordinary Share (31 March 2020: 8.82p per Ordinary Share).
Can someone pls post link to recent Ed interview. Thks.
Thks for posting Cumbrian2.
Was not aware of Ed's ~3.6% holding in Emmac.
I'm bullish on Cannabis stocks ever since Biden & Harris were elected.
Think Emmac will do well. LEAP looks interesting too.
GLA
Article on the Top Trend Takeaways in Radiology from RSNA 2020. Many relate to IQAI imv (1-4) but I esp. noted in particular No. 3 - 'There is a renewed value in partnerships'. (below)
https://www.itnonline.com/article/top-trend-takeaways-radiology-rsna-2020
COVID has opened the eyes of physicians across the continuum of care to new ways to improve care. The key trends observed at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. The underlying question throughout the conference was how can the industry take the information from this past year and learn from it?
Alan Pitt, M.D., a neuroradiologist at Barrow Neurological Institute in Phoenix, Ariz., sees the pandemic as a catalyst for change, and a way to reset how radiologists view healthcare. “We are an enabler of value of public health — taking care of as many people as possible and giving the highest value possible,” he stressed in a Philips Editor’s Roundtable during the conference. “It’s time to refocus: How many lives can we save? 2021 should be interesting. We need to keep up this level of urgency.”
There were many important takeaways from RSNA20. Here, ITN’s editors highlight their Top 7.
....
3. There is a renewed value in partnerships.
In 2020, many companies partnered with AI technology vendors to help increase productivity and accuracy. Examples include Canon partnering with Zebra, Glassbeam and Barracuda, and Konica Minolta with 1Qbit.
Artificial intelligence is a major area of partnering. Large vendors originally hoped to build out a complete menu of AI solutions, but when the reality set in that this was a daunting task that would take decades to complete, there was a rapid switch to partnering with start-up companies that already figured out algorithms, validation and had gained FDA clearance.
All of the major vendors are now offering sometime of third-party AI software in its option lineup. Some have even developed an AI marketplace, a sort of AI app store, where they can select which AI they want to try or integrate into their workflow.
---
Many thanks for posting Kainos. It's great to get some insight from someone in the field (or similar). I'm not in the medical field but the potential of the tech IB is working on is crazy imv - for example. the ability to pick up cancer cells before they are even visible on standard imaging:-
Just reading about IB CAD (Computer Aided Detection) -
'IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is accessed'
This was announced in July 2020 alongside 'a number of new ideas and projects are under preparation by the IB team' to be announced in the coming weeks and months. Since then we have had IB Trax announced with Mayo collaboration so I am expecting more news soon - new ideas/projects with new or existing collaborations hopefully.
ATB
Agreed Kiwi, Kainos. AI is the future in healthcare and a lot of investment in this field.
Interesting article on the worldwide shortage of radiologists and how ai can help.
https://www.forbes.com/sites/insights-inteliot/2020/12/09/medical-imagings-next-frontier-ai-and-the-edge/?sh=70e474ec7a80
Medical imaging is facing a problem:
"There's a worldwide shortage of radiologists," says Prashant Shah, global head of AI for Intel’s Health and Life Sciences group. "At the same time, the number of [radiology] studies is increasing at an unprecedented rate.”
To keep pace, the average radiologist interpreting computed tomography (CT) and magnetic resonance imaging (MRI) examinations would need to read an image every three-to-four seconds of an eight-hour workday, according to one study.
What’s more, says Shah, "if you burden the radiologist with more scans and ask them to read them faster, you can introduce life-critical errors.”
The solution? Many clinicians are finding it in artificial intelligence (AI) and edge computing. Thanks to these technologies, healthcare providers can process, store and analyze complex imaging data on-premises, speeding diagnosis, improving clinician workflows and saving time—and potentially lives.
^
IB tweeted this last month showing growing investment in AI.
https://www.aiin.healthcare/topics/business-intelligence/life-sciences-ai-spending
Thanks for posting Wilson63. Wish I had access to webinar. Great validation.
FWIW, here's brief snip of what IB have to offer that no-one else has (underlying technology):
IB's MRI DSC perfusion technology (earning national standard recognition) - 'It is the only MRI-DSC platform that offers truly quantitative output regardless of scanner platform, field strength, or time point and is the only commercial platform validated with tissue biopsy samples by multiple institutions. More recently, a low contrast agent dosing scheme was validated using IB Neuro. This reduced contrast alternative provides excellent agreement with the accepted double-dose protocol and is being adopted by more and more sites.'
From IB Neuro - 'For high grade tumours, IB Trax will leverage the proven technology of IB Neuro which is the only commercially available, tissue validated perfusion method that answers the most important question in neuro oncology today: "Is the enhancing region showing a tumour or is it an effect due to treatment?"
^
With the recently launched IB Stroke, I'm hoping for news, maybe re: tender? - 'The development team at IB met a very aggressive timeline and delivered on providing an extremely efficient and foundational software solution for stroke assessment'. I think someone posted a link to a tender before, not sure. Also news on StoneChecker v3: 'the Board are exploring a new initiative in telemedicine and looking at the wider application of IB technology and products', 'gad-free' patent etc...
TB converting and selling his CLN's has been blown way out of proportion imv. This provides the co with additional funds and removes the need for any placing. Looking at past RNS's, he never sold on the last spike when DS was in charge and the drift down since then was only caused by the placing at 9p and then following the decision to sell SC and instead focus resources on development of IB suite of products and the huge market opportunity these offer such as IB Neuro and IB Stroke and the 'Gad-free' project.
Time has passed and we have now developed the suite of products with partnerships in place and a sales pipeline etc. Ultimately they have changed their mind re: Stonechecker and see much greater reward in further development and release (after enquiries/trials about product). Everyone is entitled to their opinion but there is no way to know if or when TB will convert anymore shares. He may or may not - i did not know he had till 2024 so thks iphoneitrade. My guess is only if there is a need and/or poss. at a higher sp upon further updates? Whatever the case he continues to support the co. and I believe he will maintain his ~29.5% share holding. There is always the possibility of further NIH grants (applied for). Also not forgetting the 15% share buy back clause passed at the last AGM (thks, howldep).
GLA